**Core Concept**
Tacrolimus is an immunosuppressive drug that works by inhibiting **calcineurin**, a crucial enzyme in the activation of T-lymphocytes. This inhibition affects the transcription of **interleukin-2 (IL-2)**, a key cytokine involved in the immune response. The underlying mechanism involves the binding of tacrolimus to **FKBP-12** (FK506 binding protein 12).

**Why the Correct Answer is Right**
The correct answer involves the inhibition of **calcineurin**, which is a phosphatase enzyme playing a pivotal role in the dephosphorylation and subsequent translocation of **NFAT (Nuclear Factor of Activated T-cells)** into the nucleus. By inhibiting calcineurin, tacrolimus prevents the transcription of **IL-2** and other cytokines essential for T-cell activation and proliferation. This action is mediated through the formation of a complex between tacrolimus, **FKBP-12**, and **calcineurin**.

**Why Each Wrong Option is Incorrect**
**Option A:** Incorrect because while **mTOR (mechanistic target of rapamycin)** is involved in cell proliferation and survival pathways, it is not the primary target of tacrolimus.
**Option B:** Incorrect as **cyclooxygenase** is related to the synthesis of prostaglandins and is not directly related to the mechanism of action of tacrolimus.
**Option D:** Incorrect because **protein kinase C** is involved in various signaling pathways but is not the direct target through which tacrolimus exerts its immunosuppressive effects.

**Clinical Pearl / High-Yield Fact**
Tacrolimus is a potent immunosuppressant used to prevent organ rejection in transplant patients. Its narrow therapeutic index and potential for nephrotoxicity necessitate careful monitoring of blood levels and renal function.

**Correct Answer:** D. calcineurin.